{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T23:42:07Z","timestamp":1787614927328,"version":"build-2736575974"},"reference-count":92,"publisher":"IMR Press","issue":"6","license":[{"start":{"date-parts":[[2023,6,14]],"date-time":"2023-06-14T00:00:00Z","timestamp":1686700800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Basic Science Research Programme through the National Research Foundation of Korea","award":["NRF-2022R1I1A1A01070145"],"award-info":[{"award-number":["NRF-2022R1I1A1A01070145"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev. Cardiovasc. Med."],"abstract":"<jats:p>The prevalence of non-alcoholic fatty liver disease (NAFLD) is estimated to increase to over half of the adult population by 2040 globally. Since the final diagnosis of NAFLD is made by a liver biopsy, several non-invasive approaches have been developed and validated to define NAFLD and evaluate NAFLD-associated diseases. Presently, NAFLD has been identified as an important and independent risk factor for developing several extrahepatic diseases, including atherosclerosis, cardiovascular disease (CVD), diabetes, and dementia. This review discusses current findings of up-to-date literature regarding the effects of NAFLD on the risk of atherosclerosis and CVD in Asia along with potential underlying biological mechanisms and therapeutic approaches to lower the NAFLD-related CVD risk. We further focus on the difference between NAFLD and metabolic dysfunction-associated fatty liver disease (MAFLD) on the risk of CVD and its implication by comparing the risk of NAFLD and MAFLD.<\/jats:p>","DOI":"10.31083\/j.rcm2406173","type":"journal-article","created":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T01:49:25Z","timestamp":1686880165000},"source":"Crossref","is-referenced-by-count":13,"title":["Non-Alcoholic Fatty Liver Disease, Atherosclerosis, and Cardiovascular Disease in Asia"],"prefix":"10.31083","volume":"24","author":[{"given":"Yohwan","family":"Lim","sequence":"first","affiliation":[{"name":"Department of Biomedical Informatics, School of Medicine, CHA University, 13488 Seongnam, Republic of Korea"},{"name":"Institute for Biomedical Informatics, School of Medicine, CHA University, 13488 Seongnam, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seogsong","family":"Jeong","sequence":"first","affiliation":[{"name":"Department of Biomedical Informatics, School of Medicine, CHA University, 13488 Seongnam, Republic of Korea"},{"name":"Institute for Biomedical Informatics, School of Medicine, CHA University, 13488 Seongnam, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myunghee","family":"Hong","sequence":"first","affiliation":[{"name":"Department of Biomedical Informatics, School of Medicine, CHA University, 13488 Seongnam, Republic of Korea"},{"name":"Institute for Biomedical Informatics, School of Medicine, CHA University, 13488 Seongnam, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun Wook","family":"Han","sequence":"first","affiliation":[{"name":"Department of Biomedical Informatics, School of Medicine, CHA University, 13488 Seongnam, Republic of Korea"},{"name":"Institute for Biomedical Informatics, School of Medicine, CHA University, 13488 Seongnam, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16242","published-online":{"date-parts":[[2023,6,14]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Diehl AM, Day C. Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis. The New England Journal of Medicine. 2017; 377: 2063\u20132072.","DOI":"10.1056\/NEJMra1503519"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Le MH, Yeo YH, Zou B, Barnet S, Henry L, Cheung R, et al. Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach. Clinical and Molecular Hepatology. 2022; 28: 841\u2013850.","DOI":"10.3350\/cmh.2022.0239"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nature Reviews Gastroenterology & Hepatology. 2018; 15: 11\u201320.","DOI":"10.1038\/nrgastro.2017.109"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Lee KC, Wu PS, Lin HC. Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis. Clinical and Molecular Hepatology. 2023; 29: 77\u201398.","DOI":"10.3350\/cmh.2022.0237"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Quek J, Chan KE, Wong ZY, Tan C, Tan B, Lim WH, et al. Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis. The Lancet Gastroenterology & Hepatology. 2023; 8: 20\u201330.","DOI":"10.1016\/S2468-1253(22)00317-X"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Younossi Z, Aggarwal P, Shrestha I, Fernandes J, Johansen P, Augusto M, et al. The burden of non-alcoholic steatohepatitis: A systematic review of health-related quality of life and patient-reported outcomes. JHEP Reports. 2022; 4: 100525.","DOI":"10.1016\/j.jhepr.2022.100525"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Keating SE, Hackett DA, George J, Johnson NA. Exercise and non-alcoholic fatty liver disease: a systematic review and meta-analysis. Journal of Hepatology. 2012; 57: 157\u2013166.","DOI":"10.1016\/j.jhep.2012.02.023"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Chen G, Banini B, Do A, Lim J. The Independent Effect of Exercise on Biopsy-Proven Non-Alcoholic Fatty Liver Disease: A Systematic Review. Clinical and Molecular Hepatology. 2022. (online ahead of print)","DOI":"10.3350\/cmh.2022.0366"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Kaya E, Yilmaz Y. Epidemiology, natural history, and diagnosis of metabolic dysfunction-associated fatty liver disease: a comparative review with nonalcoholic fatty liver disease. Therapeutic Advances in Endocrinology and Metabolism. 2022; 13: 20420188221139650.","DOI":"10.1177\/20420188221139650"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Leivas G, Maraschin CK, Blume CA, Telo GH, Trindade MRM, Trindade EN, et al. Accuracy of ultrasound diagnosis of nonalcoholic fatty liver disease in patients with classes II and III obesity: A pathological image study. Obesity Research & Clinical Practice. 2021; 15: 461\u2013465.","DOI":"10.1016\/j.orcp.2021.09.002"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterology. 2006; 6: 33.","DOI":"10.1186\/1471-230X-6-33"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Lee JH, Kim D, Kim HJ, Lee CH, Yang JI, Kim W, et al. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Digestive and Liver Disease. 2010; 42: 503\u2013508.","DOI":"10.1016\/j.dld.2009.08.002"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Jeong S, Kim K, Chang J, Choi S, Kim SM, Son JS, et al. Development of a simple nonalcoholic fatty liver disease scoring system indicative of metabolic risks and insulin resistance. Annals of Translational Medicine. 2020; 8: 1414.","DOI":"10.21037\/atm-20-2951"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Taylan G, Ebik M, Solak S, Kaya \u00c7, Yalta K. Risk of premature coronary atherosclerosis in patients with nonalcoholic fatty liver disease. Revista Da Associacao Medica Brasileira. 2022; 68: 1428\u20131433.","DOI":"10.1590\/1806-9282.20220514"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Jeong S, Oh YH, Choi S, Chang J, Kim SM, Son JS, et al. Metabolic Dysfunction-Associated Fatty Liver Disease Better Predicts Incident Cardiovascular Disease. Gut and Liver. 2022; 16: 589\u2013598.","DOI":"10.5009\/gnl210256"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Kim HJ, Lim Y, Yoon SS, Lee SJ, Lee MH, Park H, et al. Development and validation of a nonalcoholic fatty liver disease-based self-diagnosis tool for diabetes. Annals of Translational Medicine. 2022; 10: 1158.","DOI":"10.21037\/atm-22-2195"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Jeong S, Oh YH, Choi S, Chang J, Kim SM, Son JS, et al. Association of non-alcoholic fatty liver disease with incident dementia later in life among elder adults. Clinical and Molecular Hepatology. 2022; 28: 510\u2013521.","DOI":"10.3350\/cmh.2021.0332"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Deprince A, Haas JT, Staels B. Dysregulated lipid metabolism links NAFLD to cardiovascular disease. Molecular Metabolism. 2020; 42: 101092.","DOI":"10.1016\/j.molmet.2020.101092"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism: Clinical and Experimental. 2016; 65: 1038\u20131048.","DOI":"10.1016\/j.metabol.2015.12.012"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. The Journal of Clinical Investigation. 2005; 115: 1343\u20131351.","DOI":"10.1172\/JCI200523621"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Heeren J, Scheja L. Metabolic-associated fatty liver disease and lipoprotein metabolism. Molecular Metabolism. 2021; 50: 101238.","DOI":"10.1016\/j.molmet.2021.101238"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Samuel VT, Shulman GI. Mechanisms for insulin resistance: common threads and missing links. Cell. 2012; 148: 852\u2013871.","DOI":"10.1016\/j.cell.2012.02.017"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Tanase DM, Gosav EM, Costea CF, Ciocoiu M, Lacatusu CM, Maranduca MA, et al. The Intricate Relationship between Type 2 Diabetes Mellitus (T2DM), Insulin Resistance (IR), and Nonalcoholic Fatty Liver Disease (NAFLD). Journal of Diabetes Research. 2020; 2020: 3920196.","DOI":"10.1155\/2020\/3920196"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Li W, Cao T, Luo C, Cai J, Zhou X, Xiao X, et al. Crosstalk between ER stress, NLRP3 inflammasome, and inflammation. Applied Microbiology and Biotechnology. 2020; 104: 6129\u20136140.","DOI":"10.1007\/s00253-020-10614-y"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Puri P, Mirshahi F, Cheung O, Natarajan R, Maher JW, Kellum JM, et al. Activation and dysregulation of the unfolded protein response in nonalcoholic fatty liver disease. Gastroenterology. 2008; 134: 568\u2013576.","DOI":"10.1053\/j.gastro.2007.10.039"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Muzurovi\u0107 E, Polyzos S, Mikhailidis D, Borozan S, Novosel D, Cmiljani\u0107 O, et al. Non-alcoholic fatty liver disease in children. Current Vascular Pharmacology. 2022. (Online ahead of print)","DOI":"10.2174\/1570161121666221118155136"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Fang YL, Chen H, Wang CL, Liang L. Pathogenesis of non-alcoholic fatty liver disease in children and adolescence: From \u201ctwo hit theory\u201d to \u201cmultiple hit model\u201d. World Journal of Gastroenterology. 2018; 24: 2974\u20132983.","DOI":"10.3748\/wjg.v24.i27.2974"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Fang YL, Chen H, Wang CL, Liang L. Pathogenesis of non-alcoholic fatty liver disease in children and adolescence: From \u201ctwo hit theory\u201d to \u201cmultiple hit model\u201d. World Journal of Gastroenterology. 2018; 24: 2974\u20132983.","DOI":"10.3748\/wjg.v24.i27.2974"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Chen Z, Tian R, She Z, Cai J, Li H. Role of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease. Free Radical Biology & Medicine. 2020; 152: 116\u2013141.","DOI":"10.1016\/j.freeradbiomed.2020.02.025"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Forrester SJ, Kikuchi DS, Hernandes MS, Xu Q, Griendling KK. Reactive Oxygen Species in Metabolic and Inflammatory Signaling. Circulation Research. 2018; 122: 877\u2013902.","DOI":"10.1161\/CIRCRESAHA.117.311401"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Hong T, Chen Y, Li X, Lu Y. The Role and Mechanism of Oxidative Stress and Nuclear Receptors in the Development of NAFLD. Oxidative Medicine and Cellular Longevity. 2021; 2021: 6889533.","DOI":"10.1155\/2021\/6889533"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Xu L, Nagata N, Ota T. Impact of Glucoraphanin-Mediated Activation of Nrf2 on Non-Alcoholic Fatty Liver Disease with a Focus on Mitochondrial Dysfunction. International Journal of Molecular Sciences. 2019; 20: 5920.","DOI":"10.3390\/ijms20235920"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Del Ben M, Polimeni L, Carnevale R, Bartimoccia S, Nocella C, Baratta F, et al. NOX2-generated oxidative stress is associated with severity of ultrasound liver steatosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterology. 2014; 14: 81.","DOI":"10.1186\/1471-230X-14-81"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Podszun MC, Chung JY, Ylaya K, Kleiner DE, Hewitt SM, Rotman Y. 4-HNE Immunohistochemistry and Image Analysis for Detection of Lipid Peroxidation in Human Liver Samples Using Vitamin E Treatment in NAFLD as a Proof of Concept. The Journal of Histochemistry and Cytochemistry. 2020; 68: 635\u2013643.","DOI":"10.1369\/0022155420946402"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Su\u00e1rez-Cuenca JA, Dom\u00ednguez-P\u00e9rez GA, Hern\u00e1ndez-Mu\u00f1\u00f3z RE, Hern\u00e1ndez-Patricio A, Vera-G\u00f3mez E, Guti\u00e9rrez-Buend\u00eda JA, et al. Nonalcoholic Fatty Liver Disease Severity Is Related to Plasma Pro-Oxidative Biomarkers Rather Than Liver Tissue-Measured Nitrogen Metabolism Biomarkers in Population with Obesity and Metabolic Syndrome. Metabolic Syndrome and Related Disorders. 2023. (online ahead of print)","DOI":"10.1089\/met.2022.0007"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Yi X, Liu YH, Zhou XF, Wang YJ, Deng J, Liu J, et al. The Influence of Abdominal and Ectopic Fat Accumulation on Carotid Intima-Media Thickness: A Chongqing Study. Journal of Stroke and Cerebrovascular Diseases. 2018; 27: 1992\u20131997.","DOI":"10.1016\/j.jstrokecerebrovasdis.2018.02.052"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Tan ECL, Tai MLS, Chan WK, Mahadeva S. Association between non-alcoholic fatty liver disease evaluated by transient elastography with extracranial carotid atherosclerosis in a multiethnic Asian community. JGH Open. 2018; 3: 117\u2013125.","DOI":"10.1002\/jgh3.12114"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Zheng J, Zhou Y, Zhang K, Qi Y, An S, Wang S, et al. Association between nonalcoholic fatty liver disease and subclinical atherosclerosis: a cross-sectional study on population over 40 years old. BMC Cardiovascular Disorders. 2018; 18: 147.","DOI":"10.1186\/s12872-018-0877-2"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Huang Y, Bi Y, Xu M, Ma Z, Xu Y, Wang T, et al. Nonalcoholic fatty liver disease is associated with atherosclerosis in middle-aged and elderly Chinese. Arteriosclerosis, Thrombosis, and Vascular Biology. 2012; 32: 2321\u20132326.","DOI":"10.1161\/ATVBAHA.112.252957"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Thakur ML, Sharma S, Kumar A, Bhatt SP, Luthra K, Guleria R, et al. Nonalcoholic fatty liver disease is associated with subclinical atherosclerosis independent of obesity and metabolic syndrome in Asian Indians. Atherosclerosis. 2012; 223: 507\u2013511.","DOI":"10.1016\/j.atherosclerosis.2012.06.005"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Kang JH, Cho KI, Kim SM, Lee JY, Kim JJ, Goo JJ, et al. Relationship between Nonalcoholic Fatty Liver Disease and Carotid Artery Atherosclerosis Beyond Metabolic Disorders in Non-Diabetic Patients. Journal of Cardiovascular Ultrasound. 2012; 20: 126\u2013133.","DOI":"10.4250\/jcu.2012.20.3.126"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Kim HC, Kim DJ, Huh KB. Association between nonalcoholic fatty liver disease and carotid intima-media thickness according to the presence of metabolic syndrome. Atherosclerosis. 2009; 204: 521\u2013525.","DOI":"10.1016\/j.atherosclerosis.2008.09.012"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Yamaguchi T, Morino K. Perivascular mechanical environment: A narrative review of the role of externally applied mechanical force in the pathogenesis of atherosclerosis. Frontiers in Cardiovascular Medicine. 2022; 9: 944356.","DOI":"10.3389\/fcvm.2022.944356"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Weber C, Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nature Medicine. 2011; 17: 1410\u20131422.","DOI":"10.1038\/nm.2538"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Gimbrone MA, Jr, Garc\u00eda-Carde\u00f1a G. Endothelial Cell Dysfunction and the Pathobiology of Atherosclerosis. Circulation Research. 2016; 118: 620\u2013636.","DOI":"10.1161\/CIRCRESAHA.115.306301"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Falk E. Pathogenesis of atherosclerosis. Journal of the American College of Cardiology. 2006; 47: C7\u2013C12.","DOI":"10.1016\/j.jacc.2005.09.068"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"Malek AM, Alper SL, Izumo S. Hemodynamic shear stress and its role in atherosclerosis. The Journal of the American Medical Association. 1999; 282: 2035\u20132042.","DOI":"10.1001\/jama.282.21.2035"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. Journal of Hepatology. 2020; 73: 202\u2013209.","DOI":"10.1016\/j.jhep.2020.07.045"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Eslam M, Sanyal AJ, George J, International Consensus Panel. MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology. 2020; 158: 1999\u20132014.e1.","DOI":"10.1053\/j.gastro.2019.11.312"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"Kang SH, Cho Y, Jeong SW, Kim SU, Lee JW, Korean NAFLD Study Group. From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple? Clinical and Molecular Hepatology. 2021; 27: 257\u2013269.","DOI":"10.3350\/cmh.2021.0067"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"Dietrich P, Hellerbrand C. Non-alcoholic fatty liver disease, obesity and the metabolic syndrome. Best Practice & Research. Clinical Gastroenterology. 2014; 28: 637\u2013653.","DOI":"10.1016\/j.bpg.2014.07.008"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"Wen W, Li H, Wang C, Chen C, Tang J, Zhou M, et al. Metabolic dysfunction-associated fatty liver disease and cardiovascular disease: A meta-analysis. Frontiers in Endocrinology. 2022; 13: 934225.","DOI":"10.3389\/fendo.2022.934225"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"Guo Y, Yang J, Ma R, Zhang X, Guo H, He J, et al. Metabolic Dysfunction-Associated Fatty Liver Disease Is Associated with the Risk of Incident Cardiovascular Disease: A Prospective Cohort Study in Xinjiang. Nutrients. 2022; 14: 2361.","DOI":"10.3390\/nu14122361"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"M\u00e9ndez-S\u00e1nchez N, Bugianesi E, Gish RG, Lammert F, Tilg H, Nguyen MH, et al. Global multi-stakeholder endorsement of the MAFLD definition. The Lancet Gastroenterology & Hepatology. 2022; 7: 388\u2013390.","DOI":"10.1016\/S2468-1253(22)00062-0"},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"Lee H, Lee YH, Kim SU, Kim HC. Metabolic Dysfunction-Associated Fatty Liver Disease and Incident Cardiovascular Disease Risk: A Nationwide Cohort Study. Clinical Gastroenterology and Hepatology. 2021; 19: 2138\u20132147.e10.","DOI":"10.1016\/j.cgh.2020.12.022"},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"Liu Z, Suo C, Shi O, Lin C, Zhao R, Yuan H, et al. The Health Impact of MAFLD, a Novel Disease Cluster of NAFLD, Is Amplified by the Integrated Effect of Fatty Liver Disease-Related Genetic Variants. Clinical Gastroenterology and Hepatology. 2022; 20: e855\u2013e875.","DOI":"10.1016\/j.cgh.2020.12.033"},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"Liang Y, Chen H, Liu Y, Hou X, Wei L, Bao Y, et al. Association of MAFLD With Diabetes, Chronic Kidney Disease, and Cardiovascular Disease: A 4.6-Year Cohort Study in China. The Journal of Clinical Endocrinology and Metabolism. 2022; 107: 88\u201397.","DOI":"10.1210\/clinem\/dgab641"},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"Yoneda M, Yamamoto T, Honda Y, Imajo K, Ogawa Y, Kessoku T, et al. Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: a retrospective nationwide claims database study in Japan. Journal of Gastroenterology. 2021; 56: 1022\u20131032.","DOI":"10.1007\/s00535-021-01828-6"},{"key":"ref59","doi-asserted-by":"crossref","unstructured":"Nguyen VH, Le MH, Cheung RC, Nguyen MH. Differential Clinical Characteristics and Mortality Outcomes in Persons With NAFLD and\/or MAFLD. Clinical Gastroenterology and Hepatology. 2021; 19: 2172\u20132181.e6.","DOI":"10.1016\/j.cgh.2021.05.029"},{"key":"ref60","doi-asserted-by":"crossref","unstructured":"Kim D, Konyn P, Sandhu KK, Dennis BB, Cheung AC, Ahmed A. Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States. Journal of Hepatology. 2021; 75: 1284\u20131291.","DOI":"10.1016\/j.jhep.2021.07.035"},{"key":"ref61","doi-asserted-by":"crossref","unstructured":"Huang Q, Zou X, Wen X, Zhou X, Ji L. NAFLD or MAFLD: Which Has Closer Association With All-Cause and Cause-Specific Mortality?-Results From NHANES III. Frontiers in Medicine. 2021; 8: 693507.","DOI":"10.3389\/fmed.2021.693507"},{"key":"ref62","doi-asserted-by":"crossref","unstructured":"Semmler G, Wernly S, Bachmayer S, Leitner I, Wernly B, Egger M, et al. Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)-Rather a Bystander Than a Driver of Mortality. The Journal of Clinical Endocrinology and Metabolism. 2021; 106: 2670\u20132677.","DOI":"10.1210\/clinem\/dgab339"},{"key":"ref63","doi-asserted-by":"crossref","unstructured":"Liu HH, Cao YX, Jin JL, Guo YL, Zhu CG, Wu NQ, et al. Metabolic-associated fatty liver disease and major adverse cardiac events in patients with chronic coronary syndrome: a matched case-control study. Hepatology International. 2021; 15: 1337\u20131346.","DOI":"10.1007\/s12072-021-10252-0"},{"key":"ref64","doi-asserted-by":"crossref","unstructured":"Yamamura S, Eslam M, Kawaguchi T, Tsutsumi T, Nakano D, Yoshinaga S, et al. MAFLD identifies patients with significant hepatic fibrosis better than NAFLD. Liver International. 2020; 40: 3018\u20133030.","DOI":"10.1111\/liv.14675"},{"key":"ref65","doi-asserted-by":"crossref","unstructured":"Kim Y, Han E, Lee JS, Lee HW, Kim BK, Kim MK, et al. Cardiovascular Risk Is Elevated in Lean Subjects with Nonalcoholic Fatty Liver Disease. Gut and Liver. 2022; 16: 290\u2013299.","DOI":"10.5009\/gnl210084"},{"key":"ref66","doi-asserted-by":"crossref","unstructured":"Muzurovi\u0107 E, Peng CCH, Belanger MJ, Sanoudou D, Mikhailidis DP, Mantzoros CS. Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: a Review of Shared Cardiometabolic Risk Factors. Hypertension. 2022; 79: 1319\u20131326.","DOI":"10.1161\/HYPERTENSIONAHA.122.17982"},{"key":"ref67","doi-asserted-by":"crossref","unstructured":"Ciardullo S, Monti T, Sala I, Grassi G, Mancia G, Perseghin G. Nonalcoholic Fatty Liver Disease and Advanced Fibrosis in US Adults Across Blood Pressure Categories. Hypertension. 2020; 76: 562\u2013568.","DOI":"10.1161\/HYPERTENSIONAHA.120.15220"},{"key":"ref68","doi-asserted-by":"crossref","unstructured":"Younossi ZM, Golabi P, de Avila L, Paik JM, Srishord M, Fukui N, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. Journal of Hepatology. 2019; 71: 793\u2013801.","DOI":"10.1016\/j.jhep.2019.06.021"},{"key":"ref69","doi-asserted-by":"crossref","unstructured":"Targher G, Corey KE, Byrne CD. NAFLD, and cardiovascular and cardiac diseases: Factors influencing risk, prediction and treatment. Diabetes & Metabolism. 2021; 47: 101215.","DOI":"10.1016\/j.diabet.2020.101215"},{"key":"ref70","doi-asserted-by":"crossref","unstructured":"Cho HJ, Hwang S, Park JI, Yang MJ, Hwang JC, Yoo BM, et al. Improvement of Nonalcoholic Fatty Liver Disease Reduces the Risk of Type 2 Diabetes Mellitus. Gut and Liver. 2019; 13: 440\u2013449.","DOI":"10.5009\/gnl18382"},{"key":"ref71","doi-asserted-by":"crossref","unstructured":"Katsiki N, Mikhailidis DP, Mantzoros CS. Non-alcoholic fatty liver disease and dyslipidemia: An update. Metabolism: Clinical and Experimental. 2016; 65: 1109\u20131123.","DOI":"10.1016\/j.metabol.2016.05.003"},{"key":"ref72","doi-asserted-by":"crossref","unstructured":"Tariq SM, Sidhu MS, Toth PP, Boden WE. HDL hypothesis: where do we stand now? Current Atherosclerosis Reports. 2014; 16: 398.","DOI":"10.1007\/s11883-014-0398-0"},{"key":"ref73","doi-asserted-by":"crossref","unstructured":"Wong VWS, Chan WK, Chitturi S, Chawla Y, Dan YY, Duseja A, et al. Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 1: Definition, risk factors and assessment. Journal of Gastroenterology and Hepatology. 2018; 33: 70\u201385.","DOI":"10.1111\/jgh.13857"},{"key":"ref74","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Journal of Hepatology. 2016; 64: 1388\u20131402.","DOI":"10.1016\/j.jhep.2015.11.004"},{"key":"ref75","doi-asserted-by":"crossref","unstructured":"Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018; 67: 328\u2013357.","DOI":"10.1002\/hep.29367"},{"key":"ref76","doi-asserted-by":"crossref","unstructured":"Martin K, Hatab A, Athwal VS, Jokl E, Piper Hanley K. Genetic Contribution to Non-alcoholic Fatty Liver Disease and Prognostic Implications. Current Diabetes Reports. 2021; 21: 8.","DOI":"10.1007\/s11892-021-01377-5"},{"key":"ref77","doi-asserted-by":"crossref","unstructured":"Jegatheesan P, De Bandt JP. Fructose and NAFLD: The Multifaceted Aspects of Fructose Metabolism. Nutrients. 2017; 9: 230.","DOI":"10.3390\/nu9030230"},{"key":"ref78","doi-asserted-by":"crossref","unstructured":"Anania C, Perla FM, Olivero F, Pacifico L, Chiesa C. Mediterranean diet and nonalcoholic fatty liver disease. World Journal of Gastroenterology. 2018; 24: 2083\u20132094.","DOI":"10.3748\/wjg.v24.i19.2083"},{"key":"ref79","doi-asserted-by":"crossref","unstructured":"Abenavoli L, Di Renzo L, Boccuto L, Alwardat N, Gratteri S, De Lorenzo A. Health benefits of Mediterranean diet in nonalcoholic fatty liver disease. Expert Review of Gastroenterology & Hepatology. 2018; 12: 873\u2013881.","DOI":"10.1080\/17474124.2018.1503947"},{"key":"ref80","doi-asserted-by":"crossref","unstructured":"Finer N. Weight loss interventions and nonalcoholic fatty liver disease: Optimizing liver outcomes. Diabetes, Obesity & Metabolism. 2022; 24: 44\u201354.","DOI":"10.1111\/dom.14569"},{"key":"ref81","doi-asserted-by":"crossref","unstructured":"Francque SMA, Verrijken A, Mertens I, Hubens G, Van Marck E, Pelckmans P, et al. Noninvasive assessment of nonalcoholic fatty liver disease in obese or overweight patients. Clinical Gastroenterology and Hepatology. 2012; 10: 1162\u20131168; quiz e87.","DOI":"10.1016\/j.cgh.2012.06.019"},{"key":"ref82","doi-asserted-by":"crossref","unstructured":"Stratopoulos C, Papakonstantinou A, Terzis I, Spiliadi C, Dimitriades G, Komesidou V, et al. Changes in liver histology accompanying massive weight loss after gastroplasty for morbid obesity. Obesity Surgery. 2005; 15: 1154\u20131160.","DOI":"10.1381\/0960892055002239"},{"key":"ref83","doi-asserted-by":"crossref","unstructured":"Jaskiewicz K, Raczynska S, Rzepko R, Sledzi\u0144ski Z. Nonalcoholic fatty liver disease treated by gastroplasty. Digestive Diseases and Sciences. 2006; 51: 21\u201326.","DOI":"10.1007\/s10620-006-3077-3"},{"key":"ref84","doi-asserted-by":"crossref","unstructured":"Elsaid MI, Li Y, Bridges JFP, Brock G, Minacapelli CD, Rustgi VK. Association of Bariatric Surgery With Cardiovascular Outcomes in Adults With Severe Obesity and Nonalcoholic Fatty Liver Disease. JAMA Network Open. 2022; 5: e2235003.","DOI":"10.1001\/jamanetworkopen.2022.35003"},{"key":"ref85","doi-asserted-by":"crossref","unstructured":"Kwak MS, Kim D, Chung GE, Kim W, Kim YJ, Yoon JH. Role of physical activity in nonalcoholic fatty liver disease in terms of visceral obesity and insulin resistance. Liver International. 2015; 35: 944\u2013952.","DOI":"10.1111\/liv.12552"},{"key":"ref86","doi-asserted-by":"crossref","unstructured":"S\u0142omko J, Zalewska M, Niemiro W, Kujawski S, S\u0142upski M, Januszko-Giergielewicz B, et al. Evidence-Based Aerobic Exercise Training in Metabolic-Associated Fatty Liver Disease: Systematic Review with Meta-Analysis. Journal of Clinical Medicine. 2021; 10: 1659.","DOI":"10.3390\/jcm10081659"},{"key":"ref87","doi-asserted-by":"crossref","unstructured":"Jung HS, Chang Y, Kwon MJ, Sung E, Yun KE, Cho YK, et al. Smoking and the Risk of Non-Alcoholic Fatty Liver Disease: A Cohort Study. The American Journal of Gastroenterology. 2019; 114: 453\u2013463.","DOI":"10.1038\/s41395-018-0283-5"},{"key":"ref88","doi-asserted-by":"crossref","unstructured":"Akhavan Rezayat A, Dadgar Moghadam M, Ghasemi Nour M, Shirazinia M, Ghodsi H, Rouhbakhsh Zahmatkesh MR, et al. Association between smoking and non-alcoholic fatty liver disease: A systematic review and meta-analysis. SAGE Open Medicine. 2018; 6: 2050312117745223.","DOI":"10.1177\/2050312117745223"},{"key":"ref89","doi-asserted-by":"crossref","unstructured":"Raj H, Durgia H, Palui R, Kamalanathan S, Selvarajan S, Kar SS, et al. SGLT-2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A systematic review. World Journal of Diabetes. 2019; 10: 114\u2013132.","DOI":"10.4239\/wjd.v10.i2.114"},{"key":"ref90","doi-asserted-by":"crossref","unstructured":"Barb D, Portillo-Sanchez P, Cusi K. Pharmacological management of nonalcoholic fatty liver disease. Metabolism: Clinical and Experimental. 2016; 65: 1183\u20131195.","DOI":"10.1016\/j.metabol.2016.04.004"},{"key":"ref91","doi-asserted-by":"crossref","unstructured":"Li Y, Xu H, Wu W, Ye J, Fang D, Shi D, et al. Clinical application of angiotensin receptor blockers in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis. Oncotarget. 2018; 9: 24155\u201324167.","DOI":"10.18632\/oncotarget.23816"},{"key":"ref92","doi-asserted-by":"crossref","unstructured":"Kim KM, Roh JH, Lee S, Yoon JH. Clinical implications of renin-angiotensin system inhibitors for development and progression of non-alcoholic fatty liver disease. Scientific Reports. 2021; 11: 2884.","DOI":"10.1038\/s41598-021-81959-1"}],"container-title":["Reviews in Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/RCM\/24\/6\/10.31083\/j.rcm2406173","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T13:46:54Z","timestamp":1732715214000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/RCM\/24\/6\/10.31083\/j.rcm2406173"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,14]]},"references-count":92,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023]]}},"alternative-id":["S1530-6550(23)00924-9"],"URL":"https:\/\/doi.org\/10.31083\/j.rcm2406173","relation":{},"ISSN":["1530-6550","2153-8174"],"issn-type":[{"value":"1530-6550","type":"print"},{"value":"2153-8174","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,14]]},"article-number":"173"}}